Northwest Biotherapeutics, Inc. (NWBO)
OTCMKTS
· Delayed Price · Currency is USD
0.282
-0.008 (-2.76%)
Nov 15, 2024, 4:00 PM EST
Northwest Biotherapeutics Cash Flow Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | 2018 - 2014 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '24 Sep 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 | 2018 - 2014 |
| Net Income | -69.53 | -62.6 | -105.03 | 179.13 | -529.82 | -20.81 | Upgrade
|
| Depreciation & Amortization | 1.96 | 1.73 | 1.5 | 0.59 | 0.43 | 0.02 | Upgrade
|
| Other Amortization | 1.98 | 2.37 | 2.77 | 2.3 | 3.01 | 1.43 | Upgrade
|
| Stock-Based Compensation | 4.58 | 4.41 | 12.3 | 15.5 | 52.21 | 1.82 | Upgrade
|
| Other Operating Activities | 4.32 | 4.14 | 28.48 | -238.54 | 442.12 | -10.21 | Upgrade
|
| Change in Accounts Payable | 3.19 | -4.43 | 6.85 | -0.6 | 2.13 | -3.2 | Upgrade
|
| Change in Other Net Operating Assets | -0.29 | 0.73 | 0.36 | 3.32 | -2.17 | -0.91 | Upgrade
|
| Operating Cash Flow | -53.79 | -53.64 | -52.78 | -38.3 | -32.09 | -31.86 | Upgrade
|
| Capital Expenditures | -1.35 | -3.44 | -2.9 | -6.02 | -6.61 | -0.36 | Upgrade
|
| Cash Acquisitions | - | - | - | - | -1.53 | - | Upgrade
|
| Investing Cash Flow | -1.35 | -3.44 | -2.9 | -6.02 | -8.14 | -0.36 | Upgrade
|
| Short-Term Debt Issued | - | 0.01 | 2.57 | 0.25 | 0.32 | - | Upgrade
|
| Long-Term Debt Issued | - | 33.34 | 5.6 | 29.67 | 13.67 | 7 | Upgrade
|
| Total Debt Issued | 32.56 | 33.35 | 8.17 | 29.92 | 13.99 | 7 | Upgrade
|
| Short-Term Debt Repaid | - | - | - | - | -0.38 | -5.73 | Upgrade
|
| Long-Term Debt Repaid | - | -0.39 | -5.49 | -5.83 | -1.65 | -0.42 | Upgrade
|
| Total Debt Repaid | -1.23 | -0.39 | -5.49 | -5.83 | -2.02 | -6.15 | Upgrade
|
| Net Debt Issued (Repaid) | 31.34 | 32.96 | 2.68 | 24.09 | 11.96 | 0.85 | Upgrade
|
| Issuance of Common Stock | 11.65 | 1.72 | 20.57 | 24.05 | 40.73 | 9.09 | Upgrade
|
| Other Financing Activities | 0.64 | 4.75 | - | - | 0 | 0.01 | Upgrade
|
| Financing Cash Flow | 55.26 | 52.76 | 41.97 | 48.13 | 52.7 | 9.95 | Upgrade
|
| Foreign Exchange Rate Adjustments | -3.27 | -0.52 | 5.51 | 1.37 | -2.85 | 0.42 | Upgrade
|
| Net Cash Flow | -3.16 | -4.84 | -8.2 | 5.19 | 9.61 | -21.85 | Upgrade
|
| Free Cash Flow | -55.15 | -57.07 | -55.68 | -44.31 | -38.7 | -32.22 | Upgrade
|
| Free Cash Flow Margin | -3455.39% | -2954.14% | -3308.20% | -4409.35% | -2997.91% | -1336.89% | Upgrade
|
| Free Cash Flow Per Share | -0.05 | -0.05 | -0.05 | -0.04 | -0.05 | -0.06 | Upgrade
|
| Cash Interest Paid | 0.06 | 0.06 | 0.91 | 1.73 | 0.04 | 1.02 | Upgrade
|
| Levered Free Cash Flow | -32.87 | -118.13 | -44.98 | -270 | 325.19 | -35.05 | Upgrade
|
| Unlevered Free Cash Flow | -30.78 | -117.23 | -43.96 | -269.17 | 327.52 | -34.62 | Upgrade
|
| Change in Net Working Capital | -3.67 | 85.24 | 16.44 | 246.37 | -335.62 | 18.62 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.